Novartis and Amgen expand Alzheimer's collaboration

3 November 2017

Swiss pharma giant Novartis (NOVN: VX) and US biotech Amgen (Nasdaq: AMGN), along with the Banner Alzheimer's Institute (BAI), have expanded their collaboration to initiate a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2.

This trial follows the launch of the Generation Study 1, and will determine whether the BACE1 inhibitor CNP520 - developed by Amgen and Novartis - can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population. BACE1 is an enzyme that plays an important role in the production of Amyloid ß, a protein which accumulates in the brains of individuals with AD years before clinical symptoms begin.

No financial terms of the deal were released. The new trial differs from Generation Study 1, which is funded by a $33.2 million grant from the USA’s National Institutes for Health (NIH).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK